NRC
AMAG

North Run Capital’s AMAG Pharmaceuticals AMAG Stock Holding History

North Run Capital’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-560,000
Closed -$13.7M – 25
2016
Q3 		$13.7M Buy
+560,000
New +$14M 2.16% 19

Other funds holding AMAG

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

North Run Capital's AMAG Position: Q4 2016 in Review

North Run Capital sold out of AMAG Pharmaceuticals (AMAG) in Q4 2016, closing a stake of 560,000 shares — an estimated $13.7M sold.

North Run Capital first reported a position in AMAG in Q3 2016 and held it in 1 quarter. The position peaked at $13.7M in Q3 2016. 206 funds tracked by Wall St. Rank hold AMAG as of Q4 2016.

  • North Run Capital reported no remaining AMAG Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • North Run Capital sold 560,000 AMAG Pharmaceuticals shares in Q4 2016, an estimated $13.7M.
  • North Run Capital first reported a position in AMAG Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • North Run Capital's AMAG Pharmaceuticals position peaked at $13.7M in Q3 2016.
  • 206 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2016.

Based on North Run Capital's 13F filing for Q4 2016, filed 10 Feb 2017.